Will 2017 Usher in a Brave New World for Oncology Market Access?

Posted by Howard Deutsch on Aug 25, 2016 3:03:44 PM

If you follow market access for pharmaceuticals in the United States, you know that August has become exclusion-list season for pharmacy benefit managers. Each year in early August, the two largest PBMs, CVS Health and Express Scripts, release the set of drugs that won’t be available on their formularies for the upcoming year, following contract negotiations with manufacturers. This year, for the first time, oncology drugs have shown up on an exclusion list. Specifically, CVS Health is excluding chronic myeloid leukemia treatments Gleevec and Tasigna, prostate cancer treatment Xtandi, and supportive-care drug Neupogen from its 2017 formulary. 

Read More